Literature DB >> 9247405

Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder.

H Shimon1, G Agam, R H Belmaker, T M Hyde, J E Kleinman.   

Abstract

OBJECTIVE: This study aimed to evaluate aspects of second messenger function in the brain of suicide victims and patients with bipolar disorder.
METHOD: Inositol and its synthetic enzyme, inositol monophosphatase, were measured in postmortem brain samples of 10 suicide victims, eight patients with bipolar affective disorder, and 10 normal comparison subjects.
RESULTS: The frontal cortex inositol levels of the suicide victims and the patients with bipolar disorder were significantly less than those of the normal comparison group. No differences in cerebellum or occipital cortex inositol levels were found among the three groups. The groups also showed no differences in inositol monophosphatase activity in any brain area.
CONCLUSIONS: These results could suggest a deficiency of second messenger precursor in patients with bipolar disorder and suicide victims.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247405     DOI: 10.1176/ajp.154.8.1148

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  29 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  Association of Myoinositol Transporters with Schizophrenia and Bipolar Disorder: Evidence from Human and Animal Studies.

Authors:  Marquis P Vawter; Abdul Rezzak Hamzeh; Edgar Muradyan; Olivier Civelli; Geoffrey W Abbott; Amal Alachkar
Journal:  Mol Neuropsychiatry       Date:  2019-08-08

3.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2015-02-27       Impact factor: 7.853

4.  Measuring brain uptake and incorporation into brain phosphatidylinositol of plasma myo-[2H6]inositol in unanesthetized rats: an approach to estimate in vivo brain phosphatidylinositol turnover.

Authors:  Kaizong Ma; Joseph Deutsch; Nelly E Villacreses; Thad A Rosenberger; Stanley I Rapoport; H Umesha Shetty
Journal:  Neurochem Res       Date:  2006-06-22       Impact factor: 3.996

5.  Perinatal n-3 fatty acid deficiency selectively reduces myo-inositol levels in the adult rat PFC: an in vivo (1)H-MRS study.

Authors:  Robert K McNamara; Jessica Able; Ronald Jandacek; Therese Rider; Patrick Tso; Diana M Lindquist
Journal:  J Lipid Res       Date:  2008-09-18       Impact factor: 5.922

Review 6.  In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling.

Authors:  S I Rapoport
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

7.  Inositol Hexakisphosphate Kinase 1 (IP6K1) Regulates Inositol Synthesis in Mammalian Cells.

Authors:  Wenxi Yu; Cunqi Ye; Miriam L Greenberg
Journal:  J Biol Chem       Date:  2016-03-07       Impact factor: 5.157

8.  Identification of myo-inositol-3-phosphate synthase isoforms: characterization, expression, and putative role of a 16-kDa gamma(c) isoform.

Authors:  Ratnam S Seelan; Jaganathan Lakshmanan; Manuel F Casanova; Ranga N Parthasarathy
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

Review 9.  Inositol for depressive disorders.

Authors:  M J Taylor; H Wilder; Z Bhagwagar; J Geddes
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 10.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-11       Impact factor: 3.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.